Everest Medicines Limited (1952.HK)
HKD 50.8
(3.15%)
HKD 50.8
(3.15%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 125.93 Million CNY | 884.46% |
| 2022 | 12.79 Million CNY | 23588.89% |
| 2021 | 54 Thousand CNY | 0.0% |
| 2020 | - CNY | 0.0% |
| 2019 | - CNY | 0.0% |
| 2018 | - CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 150.75 Million CNY | 0.0% |
| 2024 Q1 | 150.75 Million CNY | 157.63% |
| 2023 Q4 | 58.51 Million CNY | 0.0% |
| 2023 Q2 | 4.44 Million CNY | 0.0% |
| 2023 FY | 125.93 Million CNY | 884.46% |
| 2023 Q1 | 4.44 Million CNY | -24.28% |
| 2023 Q3 | 58.51 Million CNY | 1215.76% |
| 2022 Q3 | 5.87 Million CNY | 1025.29% |
| 2022 Q4 | 5.87 Million CNY | 0.0% |
| 2022 Q2 | 522 Thousand CNY | 0.0% |
| 2022 FY | 12.79 Million CNY | 23588.89% |
| 2022 Q1 | 522 Thousand CNY | 1833.33% |
| 2021 Q3 | 27 Thousand CNY | 0.0% |
| 2021 Q2 | - CNY | 0.0% |
| 2021 FY | 54 Thousand CNY | 0.0% |
| 2021 Q1 | - CNY | 0.0% |
| 2021 Q4 | 27 Thousand CNY | 0.0% |
| 2020 FY | - CNY | 0.0% |
| 2020 Q3 | - CNY | 0.0% |
| 2020 Q2 | - CNY | 0.0% |
| 2020 Q4 | - CNY | 0.0% |
| 2020 Q1 | - CNY | 0.0% |
| 2019 FY | - CNY | 0.0% |
| 2019 Q1 | - CNY | 0.0% |
| 2018 FY | - CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 484.71 Million HKD | 74.02% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.32 Billion HKD | 97.634% |